Welcome to our dedicated page for Universe Pharmaceuticals news (Ticker: UPC), a resource for investors and traders seeking the latest updates and insights on Universe Pharmaceuticals stock.
Universe Pharmaceuticals Inc. (NASDAQ: UPC) is a pharmaceutical producer and distributor in China with a focus on traditional Chinese medicine derivatives for elderly health and the distribution of third-party healthcare products. This news page aggregates company announcements, press releases, and market communications so readers can follow how Universe Pharmaceuticals reports on its operations, financing activities, and listing status.
In its public news releases, the company highlights developments such as financial results for interim and full-year periods, including revenue trends for its traditional Chinese medicine derivatives (TCMD) products and third-party products, changes in gross margin, and movements in operating expenses. These updates often explain how factors like economic conditions, customer demand, advertising expenditures, research and development activities, and short-term investment performance affect the company’s reported results.
Universe Pharmaceuticals also issues news about capital markets transactions and share structure changes. Examples include registered direct offerings of ordinary shares and warrants, self-underwritten public offerings of ordinary shares, and multiple share consolidations (reverse share splits) that adjust the number of ordinary shares outstanding while maintaining trading under the UPC symbol. These announcements typically describe the terms of the offerings and the share capital structure after the transactions.
Another recurring theme in the company’s news is its interaction with Nasdaq listing requirements. The company has reported receiving notifications regarding minimum bid price deficiencies, minimum Market Value of Publicly Held Shares, and delays in filing its Annual Report on Form 20-F, as well as delisting determinations subject to hearing requests. Related press releases describe the company’s stated intentions to seek hearings, request stays of suspension, or consider options such as reverse share splits to address these issues.
Investors and observers who want to follow Universe Pharmaceuticals’ financial performance, capital structure changes, and listing compliance updates can use this news feed as a central source of the company’s publicly released information.
Universe Pharmaceuticals (NASDAQ: UPC), a Chinese pharmaceutical producer and distributor, has announced a significant share consolidation plan effective March 24, 2025. The consolidation will combine every 40 ordinary shares (par value US$0.28125) into one ordinary share (par value US$11.25).
The company's shares will continue trading on the Nasdaq Capital Market under the symbol 'UPC' but with a new CUSIP number (G9442G 138). All fractional shares will be rounded up to whole numbers. Post-consolidation, the company's authorized share capital will be US$140,625,000, divided into 11,250,000 ordinary shares and 1,250,000 preferred shares, both with a par value of US$11.25 per share.
Universe Pharmaceuticals (Nasdaq: UPC), a Chinese pharmaceutical producer and distributor, announced receiving a staff determination notice from Nasdaq on February 19, 2025, due to its failure to file the Annual Report (Form 20-F) for the fiscal year ended September 30, 2024.
The delayed filing violates Nasdaq Listing Rule 5250(c)(1) and serves as an additional basis for delisting the company's securities. UPC is already before a Hearings Panel for non-compliance with Listing Rule 5550(a)(2) and has until February 26, 2025, to request a stay of suspension pending the panel's decision. The company plans to request the stay and is working to complete and file the delayed annual report.
Universe Pharmaceuticals (Nasdaq: UPC) has received a delisting notice from Nasdaq on January 29, 2025, due to its share price closing below $1 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Unlike typical cases where companies get 180 days to comply, UPC is ineligible for this grace period because it already implemented a reverse stock split on November 18, 2024.
The company has until February 5, 2025, to appeal the delisting determination to a hearing panel. If UPC appeals, its shares will continue trading on Nasdaq during the appeal process. Without an appeal, trading will be suspended on February 7, 2025. The company is exploring options to regain compliance, including considering another reverse stock split subject to shareholder approval.
Universe Pharmaceuticals (Nasdaq: UPC) has announced a $15 million registered direct offering, involving the sale of 18,750,000 ordinary shares at $0.80 per share. The agreement includes pre-funded warrants with a $0.001 exercise price and additional warrants to purchase up to 18,750,000 ordinary shares at $0.80 per share, with a 5-year term. Univest Securities is serving as the sole placement agent for the offering, which is expected to close around December 10, 2024. The offering is being conducted under a previously filed shelf registration statement that became effective on November 15, 2022.
Universe Pharmaceuticals (NASDAQ: UPC) announced a 15:1 share consolidation effective November 12, 2024. Each 15 pre-consolidation ordinary shares will automatically combine into one share with a new par value of US$0.28125. Trading under the consolidated shares will begin on November 18, 2024, maintaining the same symbol 'UPC' but with a new CUSIP number G9442G 120. Following consolidation, the company's authorized capital will be US$140,625,000, divided into 450,000,000 ordinary shares and 50,000,000 preferred shares. All fractional shares will be rounded up to whole numbers.
Universe Pharmaceuticals received a notification from Nasdaq on October 25, 2024, indicating non-compliance with the minimum bid price requirement. The company's stock failed to maintain the required $1.00 per share minimum bid price for 30 consecutive business days from September 13 to October 24, 2024. The company has been granted until April 23, 2025, to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. While this notification doesn't immediately affect the company's Nasdaq listing, failure to comply could lead to delisting. The company is considering options, including a potential reverse share split, to meet the requirement.
Universe Pharmaceuticals INC (Nasdaq: UPC) reported financial results for the first six months of fiscal year 2024 ended March 31, 2024. The company faced business uncertainties and a global economic slowdown, resulting in a 30.2% decrease in revenue to $12.9 million compared to $18.5 million in the same period last year. Key financial highlights include:
- Loss from operations of $1.7 million, compared to an income of $0.1 million in the previous year
- Net loss of $13.1 million, compared to a net loss of $0.7 million in the previous year
- Loss per share of $3.59, compared to $0.20 in the previous year
The company is focusing on developing online sales channels and implementing digital marketing strategies to improve brand recognition and expand its customer base. On July 15, 2024, Universe Pharmaceuticals closed a self-underwritten public offering, raising $25 million before expenses.
FAQ
What is the current stock price of Universe Pharmaceuticals (UPC)?
What is the market cap of Universe Pharmaceuticals (UPC)?
